How to Switch from Compounded Tirzepatide to Foundayo
Compounded tirzepatide faces the same FDA crackdown. Here's your path to an FDA-approved oral alternative.
Why Compounded Tirzepatide Is at Risk
Tirzepatide compounding faces increasing FDA scrutiny:
- Lilly has aggressively pursued legal action against compounding pharmacies
- As Zepbound supply stabilizes, the shortage exemption becomes harder to justify
- Multiple FDA warnings about compounded tirzepatide quality issues
The writing is on the wall. Switch to an FDA-approved option before your compounding source disappears.
What Changes: Tirzepatide vs Orforglipron
This is a bigger pharmacological change than switching between semaglutide products:
- Compounded tirzepatide: Dual GIP/GLP-1 agonist (same as Mounjaro/Zepbound)
- Foundayo: GLP-1-only partial agonist
- You lose the GIP component, which may mean slightly reduced appetite suppression
- However, Foundayo's side effect profile is generally milder
Step-by-Step: How to Make the Switch
Cost Comparison
| Medication | Self-Pay/mo | With Savings Card |
|---|---|---|
| Compounded tirzepatide | $300-600/mo | N/A |
| Foundayo | $149-349/mo | $25/mo |
Calculate Your Personalized Switch Plan
Enter your current medication and dose to get a detailed switching plan with dose mapping, timeline, and cost analysis.
Frequently Asked Questions
Sources & Citations
- FDA enforcement actions against tirzepatide compounders (2024-2026)
- Foundayo (orforglipron) FDA Prescribing Information
- Lilly legal filings against compounding pharmacies
Stay Updated
Get notified when Foundayo pricing changes, new GLP-1 options become available, or new switching data is published.Plus personalized updates for your Compounded Tirzepatide → Foundayo switch.
No spam. Unsubscribe anytime. We never share your email.
Ready to Make the Switch?
Talk to a doctor about switching to Foundayo. These telehealth providers offer online consultations and GLP-1 prescriptions.
MedSwitcher may earn a commission from some providers. This does not affect our recommendations. Our switch plans are based on clinical data, not partnerships.